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Interactions of the extracellular matrix component
hyaluronic acid and its cellular receptors CD44 and
RHAMM/IHABP have been linked to tumor pro-
gression and metastasis formation. We investigated
the expression and hyaluronic-acid-dependent func-
tions of CD44 and RHAMM/IHABP in human mel-
anoma. Immunohistochemistry of tumor specimens
at different stages of melanoma progression revealed
an increased expression of CD44 and RHAMM/
IHABP. High mRNA expression of CD44 was found
in three highly tumorigenic melanoma cell lines
compared with less tumorigenic melanoma cells or
nontransformed melanocytes. RHAMM/IHABP
expression was upregulated in all cell lines analyzed
but not in melanocytes. In contrast to the cell surface
localization of CD44, RHAMM/IHABP was detected
exclusively within the cytoplasm of melanoma cells.
Binding and adhesion of melanoma cells to hyaluro-
nic acid is mainly CD44 dependent as it was inhib-
ited to 60%±80% by an anti-CD44 monoclonal
antibody whereas anti-RHAMM/IHABP sera had no
effect. Culture of melanoma cells in the presence of
hyaluronic acid resulted in a dose-dependent, CD44-
mediated increase of melanoma cell proliferation and
enhanced release of basic ®broblast growth factor
and transforming growth factor b1. We conclude
that (i) the expression of CD44 and RHAMM/
IHABP is increased during melanoma progression,
(ii) CD44 is the principal hyaluronic acid surface
receptor on melanoma cells, and (iii) the hyaluronic-
acid-induced increase of the proliferative capacity of
melanoma cells is mainly dependent on CD44±hya-
luronic acid interactions. Key words: CD44/hyaluronic
acid/IHABP melanoma. J Invest Dermatol 116:93±101,
2001
T
he glycosaminoglycan hyaluronic acid (HA) is a
ubiquitous component of the extracellular matrix
(ECM). It has been implicated in a variety of diseases,
homeostasis, and developmental processes (Laurent
and Fraser, 1992). Several studies have correlated
increased HA synthesis with cancer progression and metastasis
(Delpech et al, 1997). Invasive tumor cells express HA receptors
and are surrounded by an HA-rich ECM (Knudson et al, 1989).
HA on the surface of the mouse B16-F1 melanoma cell line was
correlated with metastatic potential (Zhang et al, 1995). Further-
more, the level of HA synthesis was increased in highly metastatic
melanoma (MM) cell lines (van Muijen et al, 1995; Goebeler et al,
1996) and migration of MM cells is associated with increased HA
synthesis (Ichikawa et al, 1999). The capacity of HA to induce cell
proliferation has been shown in a number of experimental systems
(West and Kumar, 1989; Hamann et al, 1995; Kaya et al, 1997; Ra®
et al, 1997). Several proteins with speci®c af®nity for HA have been
identi®ed. Cartilage link protein, hyaluronectin, aggrecan, brevi-
can, and versican, for example, are components of the ECM that
bind HA (for review see Lesley et al, 1993; Iozzo and Murdoch,
1996). In addition, three cellular receptors of HA have been
described to date, namely CD44 (Aruffo et al, 1990), RHAMM/
IHABP (Turley et al, 1991), and just recently LYVE-1 (Banerji et al,
1999).
The human CD44 family of proteins comprises numerous
different isoforms that arise through differential expression of up to
19 exons of the CD44 gene (Screaton et al, 1992). Alternative
splicing of the pre-mRNA and different degrees of post-
translational glycosylation processes result in molecular weights of
CD44 isoforms ranging from 85 to 200 kDa (for review see Lesley
et al, 1993; Naor et al, 1997). CD44s, the standard isoform of the
molecule lacking variant epitopes (85±90 kDa), is expressed
ubiquitously on the cell surface of many cell types and on a variety
of malignant tumors (Horst et al, 1990; Joensuu et al, 1993; Mayer
et al, 1993). CD44s binds to HA via conserved sequence motifs
located in the extracellular constant part of the molecule (Yang et al,
1994; Bajorath et al, 1998). The expression of nine alternatively
spliced exons (v2-v10) results in a high heterogeneity of
differentially expressed isoforms, which have been implicated to
play a role in tumor progression (Heider et al, 1993; Wielenga et al,
1993; Dall et al, 1994; Penno et al, 1994) and binding of different
glycosaminoglycans, including HA (Sleeman et al, 1997). In
addition to cell adhesion, binding of CD44 to HA is also involved
in several other cellular processes like migration (Thomas et al,
1992) and proliferation (Galandrini et al, 1994; Hamann et al, 1995;
Ra® et al, 1997).
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The RHAMM/IHABP protein (receptor for HA-mediated
motility/intracellular HA-binding protein) was originally described
as an HA surface receptor that mediates cell locomotion of H-ras
transformed murine ®broblasts (Turley et al, 1991; Hardwick et al,
1992). Overexpression of the proposed RHAMM isoform v4 in
murine ®broblasts was able to induce metastasis formation (Hall et al,
1995). A human RHAMM cDNA was cloned from a breast
carcinoma cell line and a polyclonal anti-RHAMM serum
recognized several proteins with sizes of 85 kDa and possible
isoforms of 70 and 60 kDa (Wang et al, 1996). In human cancer
RHAMM/IHABP expression has been shown so far in pancreatic
cancer cells (Assmann et al, 1996), breast carcinoma cell lines (Wang
et al, 1996; Assmann et al, 1998), and lung carcinoma cell lines
(Teder et al, 1995). Several reports (Assmann et al, 1998; 1999;
Hofmann et al, 1998a) suggested that RHAMM is not a cell surface
molecule. RHAMM/IHABP was detected as an HA-binding
protein within the cytoplasm of breast carcinoma cells (Assmann
et al, 1998) and in a panel of mouse ®brosarcoma cell lines
(Hofmann et al, 1998a), leading to the af®x IHABP (intracellular
HA-binding protein). Intercellular adhesion molecule 1 (ICAM-1),
an additional adhesion receptor, has been discussed as prognostic
marker in the course of MM (Johnson et al, 1989). ICAM-1 was
also described as a cellular HA receptor (McCourt et al, 1994;
Gustafson et al, 1995). Evidence published recently by the same
authors, however, makes an HA-binding function of ICAM-1
unlikely (McCourt and Gustafson, 1997).
Metastatic MM is one of the most invasive human cancers, the
incidence of which has rapidly risen in the past decade. The process
of melanoma metastasis is characterized by distinct stages (Herlyn,
1990; Fidler, 1996) and eventually leads to both lymphatic and
hematogeneic spread of primary tumor cells and colonization at
secondary sites. The expression of different CD44 isoforms and
ICAM-1 has been implicated in tumor progression and the
metastatic potential of MM (Johnson et al, 1989; Manten-Horst
et al, 1995; Simon et al, 1996; Dietrich et al, 1997); no mechanistic
clue has been proposed, however. The in¯uence of HA on the
proliferative capacity of MM cells and the possible impact of HA on
autocrine growth factor production has not been addressed so far.
In an attempt to assess the individual contribution of CD44,
RHAMM/IHABP and, in comparison, ICAM-1 to MM progres-
sion we ®rst investigated the expression of these cellular receptors in
vivo and in vitro and then further analyzed the functional
consequences of their interaction with HA during MM carcino-
genesis.
MATERIALS AND METHODS
Media and reagents MM cells were cultured in RPMI 1640 (Seromed,
Eching, Germany) supplemented with penicillin G (50 U per ml; Gibco,
Eggenstein, Germany), streptomycin (50 mg per ml; Gibco), 2 mM L-
glutamine (Gibco), and 10% heat-inactivated fetal bovine serum (PAA,
Coelbe, Germany). Cultures of nontransformed melanocytes were
maintained in selective melanocyte growth medium (Promo Cell,
Heidelberg, Germany). Rooster comb HA (Sigma, Deisenhofen,
Germany) was used for HA-binding studies. Hyaluronidase from
Streptomyces hyaluronlyticus was purchased from Calbiochem (Frankfurt,
Germany). Fluorescein isothiocyanate (FITC) labeling (Sigma) of HA was
performed according to published methods (de Belder and Wik, 1975).
The enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems,
Abingdon, U.K.) for the determination of the MM cell speci®c growth
factors and cytokines interleukin 1a (IL-1a), transforming growth factor
b1 (TGF-b1), platelet-derived growth factor AB (PDGF-AB), IL-6, IL-8,
growth-related oncogene a (Gro-a), tumor necrosis factor a (TNF-a),
granulocyte-macrophage colony-stimulating factor (GM-CSF), and basic
®broblast growth factor (bFGF) were used according to the manufacturer's
instructions.
Cell lines The MM cell line HT144 was obtained from the ATCC
(Rockville, MD), MM1 cells were provided by Dr. Hennig (Department
of Dermatology, Freiburg, Germany), the MM cell lines MV3 and 1F6
were a gift of Dr. G.N. van Muijen (Department of Pathology, Nijmegen,
The Netherlands), and SB1 and SB3 cells were a gift of Dr. C.V. Hamby
(New York Medical College, Valhalla, NY). In our hands, the cell lines
MV3, HT144, and 1F6 have been characterized by rapid local tumor
growth in MF1 nu/nu mice after injection of 5 3 106 cells per animal (data
not shown and van Muijen et al, 1995). Cultures of nontransformed
melanocytes and keratinocytes were established from human neonatal
foreskin as described previously (Simon et al, 1996). Purity (> 95%) of the
melanocyte cultures was con®rmed by ¯uorescence-activated cell sorter
(FACS) analysis with melanocyte-speci®c monoclonal antibodies (MoAb)
HMB-45 and S100. Second to ®fth passage melanocyte cultures (P1-P5)
were used for all experiments. Cultures were maintained at 37°C in a
humidi®ed 5% CO2 atmosphere.
MoAb and staining reagents MoAb against the following human
antigens were used: anti-panCD44 (LEU44, mIgG1) and mIgG1 control
MoAb were obtained from Becton Dickinson (Heidelberg, Germany),
anti-ICAM-1 (84H10, mIgG1) was purchased from Immunotech
(Marseille, France), anti-panCD44 (BU75, mIgG1) was obtained from
The Binding Site (Birmingham, U.K.), anti-panCD44 (MEM85, mIgG1)
was purchased from Monosan (Uden, The Netherlands), anti-panCD44
(Hermes3, mIgG1) was a generous gift of Dr. S. Jalkanen (University of
Turku, Finland), anti-CD44v9 (FW11.24, mIgG1) was obtained from
ATCC, anti-MAA (HMB-45, mIgG1) was procured from Ortho
(NeckargemuÈnd, Germany), and anti-S100 (S100, rabIgG) was obtained
from Dako (Hamburg, Germany). The polyclonal rabbit antihuman IkB
antibody was obtained from Santa Cruz (Heidelberg, Germany). The
polyclonal rabbit antimouse RHAMM/IHABP serum (crossreactive to
human RHAMM/IHABP) and the polyclonal rabbit antihuman
RHAMM/IHABP serum have been described elsewhere (Assmann et al,
1998; Hofmann et al, 1998a). Horseradish peroxidase conjugated goat
antirabbit IgG (H + L) was procured from Boehringer Ingelheim
(Ingelheim, Germany) and horseradish peroxidase conjugated goat
antimouse IgG was obtained from Dako.
Northern blot analysis Total cellular RNA was extracted following
standard protocols (Chomczynski and Sacchi, 1987). Fifteen micrograms of
total cellular RNA were size fractionated on 1% formaldehyde agarose gels,
transferred onto Hybond nylon N+-membranes (Amersham,
Braunschweig, Germany) in 10 3 sodium citrate/chloride buffer (SSC),
and baked at 80°C for 1 h. For blot hybridization a polymerase chain
reaction ampli®ed 770 bp human RHAMM/IHABP fragment
(corresponding to position 951±1719 of the cDNA published by
Assmann et al, 1998), a 580 bp human ICAM-1 cDNA fragment
(Johnson et al, 1989), and a 300 bp human CD44s cDNA fragment,
respectively, were [32P]-labeled by the random primer method (Stratagene,
Heidelberg, Germany). After washing with 1 3 SSC/1% sodium dodecyl
sulfate (SDS) at 65°C, the blots were exposed for autoradiography.
Subsequent hybridizations were performed after stripping the blot in 0.1 3
SSC/1% SDS at 90°C for 1 h.
Western blot analysis MM cells, nontransformed cultured melanocytes,
the cervix carcinoma cell line HeLa, and the RHAMM/IHABP positive
breast cancer cell lines T47D and MCF7 were incubated in 1 ml of a lysis
buffer containing 0.5% Nonidet P-40 (Sigma) in phosphate-buffered saline
(PBS; Gibco) and 2 mM phenylmethylsulfonyl ¯uoride (Sigma) for 30 min
on ice. After centrifugation at 14,000 rpm for 10 min, 25 mg of the total cell
lysate were separated by SDS polyacrylamide gel electrophoresis (PAGE;
8% polyacrylamide gel) and electrically transferred to PVDF membranes
(Millipore, Eschborn, Germany). RHAMM/IHABP protein was detected
using the polyclonal rabbit antihuman RHAMM/IHABP serum at a
dilution of 1:500 and indirect immunoperoxidase staining was performed
with a 1:3000 diluted horseradish peroxidase conjugated goat antirabbit
IgG. Protein bands were visualized using the enhanced chemiluminescence
detection system (Amersham). As control for equal protein loading, blots
were stripped and reincubated with a 1:2000 dilution of a polyclonal serum
against the intracellular ERK (extracellular signal-regulated kinase) protein
(Santa Cruz).
Subcellular protein fractionation of total cell lysates Subcellular
protein fractionation was performed as follows. 5 3 108 cells were
harvested and resuspended in 6 ml of a cold isotonic HEPES buffer [1 mM
MgCl2, 0.5 mM CaCl2, 1 mM dithiothreitol (DTT), 20 mM HEPES
pH 8.1, and 0.11 M NaCl]. After centrifugation cells were incubated for
5 min at 4°C in 4.5 ml of a hypotonic HEPES buffer (1 mM MgCl2,
0.5 mM CaCl2, 1 mM DTT, and 20 mM HEPES pH 8.1). Then cells were
lyzed on ice by dounce homogenization (20 strokes) and an aliquot of
500 ml was saved as total cellular protein lysate. The remaining lysate was
centrifuged at 600g for 15 min at 4°C. The supernatant was transferred to
an ultracentrifuge tube and centrifuged at 250,000g for 1 h at 4°C. The
94 AHRENS ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
pellet and supernatant were used as membrane and cytoplasmic protein
fractions, respectively. Equal amounts of protein were subjected to SDS-
PAGE and Western blotting was performed as described above. The anti-
panCD44 MoAb Hermes 3 was used in a 1:1000 dilution, the anti-IkB
antibody was used 1:2000.
Immunohistochemistry Immunohistochemical stainings were
performed as described previously (Simon et al, 1996) using punch
biopsies from patients with primary tumors of MM (PMM; n = 6),
cutaneous metastasis of MM (n = 5), or with benign melanocytic nevi
(BMN; n = 7) at the time of surgery. Samples were snap-frozen and stored
in liquid nitrogen until use. In brief, sections were incubated with MoAb
against panCD44 (LEU44), ICAM-1 (84H10), polyclonal rabbit
antihuman RHAMM/IHABP serum, or rabbit preimmune serum as
control. Secondary staining was performed using the LSAB kit (Dako)
according to the manufacturer`s instructions. Staining was evaluated with a
Zeiss Axioskop (Zeiss, GoÈttingen, Germany).
Flow cytometry MM cells and melanocytes at 106 cells per ml PBS were
stained with anti-panCD44 MoAb BU75 (2 mg per ml), anti-ICAM-1
MoAb 84H10 (2 mg per ml), anti-CD44v9 MoAb FW11.24 (10 mg per ml),
polyclonal rabbit antimouse RHAMM/IHABP serum (1:10 dilution),
polyclonal rabbit antihuman RHAMM/IHABP serum (1:10 dilution), an
mIgG1a control MoAb (2 mg per ml), and rabbit preimmune serum (1:10
dilution). Cells were washed twice and then stained with the relevant
FITC-labeled goat antimouse IgG or goat antirabbit IgG. All stainings were
performed at 4°C for 45 min. Where indicated, cells were permeabilized
using the Fix & Perm kit from Dianova (Hamburg, Germany). Cell
suspensions were analyzed using a FACScan, equipped with the
CellQuestq research software (Becton Dickinson).
HA-binding assays HA (1 mg per ml NaHCO3 buffer, pH 9.6) was
®xed on 96-well ¯at bottom plates (Greiner, Frickenhausen, Germany)
overnight at 4°C. In addition, melanoma cells were radioactively labeled
overnight with 1 mCi [3H]-thymidine (Amersham) per ml medium.
Subsequently HA-coated plates were washed three times with PBS
without Ca2+/Mg2+. To avoid unspeci®c binding, plates then were
coated with 1% (wt/vol) heat-denatured bovine serum albumin (BSA;
Sigma) in PBS for 1 h at 37°C and washed again with PBS. 5 3 104 of the
labeled cells were seeded per well and plates were incubated for 30 min at
4°C. After rinsing the wells three times with PBS nonadherent cells were
removed and the remaining adherent cells were harvested and counted
using a liquid scintillation b-counter (Top-Count, Canberra Packard,
Dreieich, Germany). For antibody blocking experiments, cells were
preincubated with MoAb (10 mg per ml) for 45 min at 4°C and then
transferred to 96-well plates. As control, adhesion on 1% BSA-coated
plastic and adhesion on hyaluronidase-treated wells (10 U per ml, 37°C for
30 min) was measured. Percentage of cell binding was determined as counts
per minute of adherent cells to total counts of the initially applied 5 3 104
cells (= 100%). For HA-binding studies using soluble HA-FITC, cells were
incubated with 100 mg per ml HA-FITC for 30 min at 4°C, washed twice
with PBS, and analyzed using the FACScan. For blocking experiments cells
were preincubated with MoAb (20 mg per ml) for 45 min at 4°C before
HA-FITC was added.
Proliferation assays Ninety-six-well ¯at bottom plates (Falcon,
Heidelberg, Germany) were coated overnight at 4°C with 100 ml of
0.01 mg per ml, 0.1 mg per ml, or 1.0 mg per ml HA. After extensive
washing of the wells with PBS, 2500 cells were plated in each well. Effects
of soluble HA on cell proliferation were determined by adding soluble
heat-inactivated HA directly into the culture medium in ®nal
concentrations of 0.1 mg per ml and 1.0 mg per ml. In order to measure
cell proliferation 1 mCi [3H]-thymidine per well was added. To test for
CD44-mediated effects on cell proliferation, MM cells were preincubated
with the indicated MoAb (10 mg per ml) for 45 min at 4°C and then seeded
into the wells. After 24 h an additional 5 mg per ml of MoAb were added
per well. After a total of 48 h cells were harvested and [3H]-thymidine
uptake was determined using the Top-Count b-counter (Canberra
Packard). Statistical analysis of data sets was performed applying Student's
t test. Asterisks indicate a statistically signi®cant induction of proliferation.
RESULTS
Increased expression of CD44, ICAM-1, and RHAMM/
IHABP during melanoma progression in vivo Expression of
CD44, ICAM-1, and RHAMM/IHABP in tumor specimens of
MM patients was ®rst assessed by immunohistochemical analysis
(Table I). Cryostat sections of BMN, PMM, and MM metastases
(MMM) were stained with MoAb against panCD44 epitopes,
ICAM-1, or with a polyclonal serum against human RHAMM/
IHABP. As control, sections were stained with isotype-matched
control MoAb (data not shown) or with rabbit preimmune serum.
As shown in Fig 1, CD44 is expressed on melanocytes of BMN but
increasingly by tumor cells of PMM and MMM. Red staining
indicates positive immunoreactivity; brown staining observed in
some of the sections is due to the endogenous pigmentation of
melanocytic cells. ICAM-1 expression on PMM and MMM was
detected on melanoma cells and intratumoral endothelial cells but
not in BMN (Fig 1, Table I). RHAMM/IHABP is expressed in
the cytoplasm of melanoma cells in PMM and MMM lesions as
well as intratumoral vessels. In BMN weak immunoreactivity of
RHAMM/IHABP was detectable (Fig 1, Table I), con®rming and
extending data of basal expression levels of RHAMM/IHABP in
different murine tissues (Fieber et al, 1999). We note an increased
expression of CD44, ICAM-1, and RHAMM/IHABP in sections
of PMM and MMM in vivo.
CD44, ICAM-1, and RHAMM/IHABP mRNA expression is
increased in rapidly growing human melanoma cell
lines The in vivo stainings suggested an enhanced expression of
CD44, ICAM-1, and RHAMM/IHABP to be associated with the
proliferative capacity of human melanoma. We were interested in
whether these differences of HAR expression are also observed in
melanoma cell lines. Figure 2 shows a northern blot analysis of a
panel of different human MM cell lines and melanocyte
preparations. CD44 is expressed in all MM cell lines (Fig 2, lanes
1±6), in cultured nontransformed melanocytes (Fig 2, lanes 7±10),
and in keratinocytes (Fig 2, lane 11). A markedly increased steady-
state level of CD44 transcription is observed, however, in the cell
lines MV3, HT144, and 1F6 (Fig 2, lanes 1±3), which also show an
enhanced local tumor growth in nu/nu mice (data not shown).
CD44 mRNA expression in the MM cell line MM1 (Fig 2, lane 4)
was markedly decreased compared with the metastatic cell lines,
resulting also in a decreased CD44 protein expression. Of note, the
CD44-low-expressing MM cell line MM1 also displays a reduced
HA-binding capacity (data not shown). RHAMM/IHABP mRNA
expression is increased in all MM cell lines tested compared with
melanocytes and keratinocytes (Fig 2, lanes 1±6 and 7±11,
respectively). Although we prepared the different melanocyte
cultures in the same way, we found basal RHAMM/IHABP
expression in several melanocyte preparations. A low basal
RHAMM/IHABP mRNA expression in nontransformed
melanocyte and keratinocyte cultures should therefore be noted.
As shown in Fig 1, weak immunoactivity of RHAMM/IHABP in
some immunhistochemical stainings of BMN was detected which is
in agreement with a ubiquitous expression of RHAMM/IHABP in
different nontransformed murine tissues (Fieber et al, 1999). The
upregulation of RHAMM/IHABP expression in melanoma cell
lines is nevertheless signi®cant. Using the 770 bp human
RHAMM/IHABP cDNA probe for RNA hybridization we did
not detect additional RHAMM/IHABP mRNA transcripts. Two
Table I. CD44, ICAM-1, and RHAMM/IHABP are highly
expressed in patients suffering MM metastases
panCD44a ICAM-1 RHAMM/IHABP
BMNb 7/7c 0/7 0/7
PMM 6/6 2/6 5/6
MMM 5/5 4/5 5/5
aSections were incubated with MoAb against human panCD44, ICAM-1, and a
polyclonal serum against RHAMM/IHABP.
bCryosections of BMN, PMM, and MMM were analyzed.
cPositive immunoreactivity (positive staining > 50% of all melanocytic cells) in
sections compared with the total number of sections stained.
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ICAM-1 transcripts were detected in all MM cell lines analyzed,
con®rming previous reports (Johnson et al, 1989). Only low
ICAM-1 expression was found in melanocyte cultures and no
signal was detectable in keratinocytes (Fig 2, ICAM-1). The results
of the northern blot analysis indicate a correlation between CD44,
ICAM-1, and RHAMM/IHABP mRNA expression and the
proliferative potential of MM cells compared with nontransformed
primary melanocytes.
Surface expression of CD44, ICAM-1, and cytoplasmic
localization of RHAMM/IHABP in human melanoma
cells To con®rm the RNA expression data at the protein level
FACS stainings were performed to analyze expression levels and
localization of the different receptors in MM cell lines (Fig 3A).
PanCD44 epitopes detected by MoAb BU75 and MEM85 and
ICAM-1 epitopes were found on the cell surface of all melanoma
cell lines tested (shown for 1F6 in Fig 3A). Incubations with anti-
CD44 variant MoAb revealed only weak expression of CD44
variant epitopes on melanoma cells (data not shown). RHAMM/
IHABP could not be detected on the surface of the cell lines
analyzed (Fig 3B, ``M''). After permeabilization, however, we
observed a speci®c cytoplasmic signal for RHAMM/IHABP
(Fig 3B, ``C''). In nontransformed primary melanocytes only very
weak or no intracellular expression of RHAMM/IHABP was
detected (data not shown). To con®rm the exclusively intracellular
expression of RHAMM/IHABP we prepared membrane and
cytosolic protein fractions of MM cell lysates. Figure 3(C) shows
that RHAMM/IHABP is clearly located in the cytosolic fraction C
and not in the membrane protein fraction M. As control for the
subcellular fractionation protocol, incubations with MoAb against
the cytosolic protein IkB and CD44 as membrane protein were
performed (Fig 3C). Of note, the 70 kDa CD44 protein in the
cytosolic fraction is the CD44 precursor protein. Figure 3(D)
shows a Western blot of total cell lysates of six MM cell lines, a
melanocyte preparation, and the two RHAMM/IHABP positive
cell lines T47D and MCF7. To control for equal protein loading
the blot was incubated with a polyclonal serum against the ERK
protein (Boulton et al, 1991), which is evenly expressed in these cell
lines. Using the antihuman RHAMM/IHABP serum a speci®c 85±
90 kDa protein was detected in all cell lines analyzed (Fig 3D). No
RHAMM/IHABP protein expression was found in a protein lysate
of a melanocyte preparation (Fig 3D, Mel8 P4). It should be noted,
however, that protein loading in the melanocyte lysate sample was
somewhat lower than protein amounts loaded for the MM cell
lines, which may indicate a low albeit undetectable basal expression
of RHAMM/IHABP in nontransformed melanocytes. In addition
to the 85±90 kDa protein species, speci®c bands at 72±76 kDa were
detected that could account for splice variants, degradation
products, or modi®cations of the RHAMM/IHABP protein. To
check for speci®city of the 85±90 kDa and the 72±76 kDa band, the
blot was again incubated with the rabbit preimmune serum where
no staining of these bands was observed (data not shown).
CD44 is the principal HA receptor on human
melanoma CD44 and RHAMM/IHABP are highly expressed
in human MM cells. We wished to determine which HAR is
particularly important for the capacity of MM cells to interact with
HA. To address this issue we performed HA-binding assays using
plastic immobilized HA or FITC-labeled soluble HA. An HA-
FITC binding experiment is shown in Fig 4(A) for the cell line
MV3. MV3 cells display a high speci®c avidity for soluble HA-
FITC (mean ¯uorescence intensity MFI = 100). After
preincubation of cells with anti-panCD44 MoAb BU75
(MFI = 35) and MEM85 (MFI = 34), both of which have been
shown to interfere with HA binding of CD44 (Levesque and
Haynes, 1996), HA-FITC binding was inhibited by 60%±80%. In
the same assays antibodies against ICAM-1 (MFI = 95) and a mouse
IgG1a control (MFI = 105) had no effect. Similar results were
obtained when adhesion of MM cells to immobilized HA was
studied (Fig 4B). Again, preincubation of cells with the anti-
panCD44 MoAb BU75 inhibited cell adhesion on HA by 60%. By
contrast, MoAb against ICAM-1, a rabbit serum control, as well as
Figure 1. Increased expression of CD44 and RHAMM/IHABP in vivo. Punch biopsies from patients with PMM (n = 6), cutaneous MMM (n = 5), or
BMN (n = 7) were taken at the time of surgery. Staining was performed by incubation of sections with MoAb against panCD44 (aCD44), ICAM-1
(aICAM-1), a polyclonal rabbit antihuman RHAMM/IHABP serum (aRHAMM/IHABP), or rabbit preimmune serum as control (Control). Secondary
staining (red color) was performed using the LSAB-kit (Dako) according to the manufacturer¢s instructions. Arrows indicate CD44, ICAM-1, or RHAMM/
IHABP expressing metastatic melanoma cells, respectively.
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all polyclonal sera against RHAMM/IHABP did not affect HA
binding (Fig 4B). HA binding and adhesion of MM cells to HA is
mainly dependent on interactions of CD44 with HA. This is also
true for MM cell lines expressing low amounts of CD44 and
nontransformed melanocytes (data not shown). HA binding of
melanoma cells was never inhibited completely by CD44
antibodies, arguing for alternative cell surface HA receptors in
cells of melanocytic origin.
HA interaction with CD44 promotes melanoma cell
proliferation In an attempt to identify functional consequences
of CD44-mediated binding of melanoma cells to HA, MM cells
were cultivated for 48 h either on HA-coated surfaces or in the
presence of soluble HA in the culture medium. Cell proliferation
was determined as [3H]-thymidine incorporation for a total of 48 h.
To exclude the in¯uence of growth factors accidently
contaminating the rooster comb HA preparation that was used in
these experiments, the HA was subjected to heat inactivation for
20 min at 100°C before use. In contrast to primary cultures of
melanocytes where no HA-induced increase of proliferation was
observed (data not shown), in Fig 5(A) the HA-concentration-
dependent increase of MM cell proliferation within 48 h is shown.
The basal proliferation of MM cells (25,800 6 512 cpm) within
48 h was set as 100% proliferation (Fig 5A, Control). This basal
proliferation was increased by 35%±40% when cells were cultured
on surfaces coated with 0.1 mg per ml HA (33,344 6 2484 cpm) or
1.0 mg per ml HA (33,937 6 2611 cpm) (Fig 5A, 0.1 mg per ml
HA, 1.0 mg per ml HA). Surfaces coated with 0.01 mg per ml HA
(27,398 6 898 cpm) induced a slight increase of MM cell
proliferation (Fig 5A, 0.01 mg per ml HA). Soluble HA (Fig 5A,
0.1 mg per ml sol HA and 1.0 mg per ml sol HA) added to MM cell
cultures also induced a 30%±35% increase of MM cell proliferation
(33,756 6 1917 cpm for 0.1 mg per ml sol HA and 31,687 6 1189
cpm for 1.0 mg per ml sol HA, respectively).
The HA-induced proliferation was blocked almost completely
by preincubation of MM cells with the anti-panCD44 MoAb
BU75 (Fig 5B). Again, the basal proliferation (22,942 6 3223) was
set as 100% (Fig 5B, Control). No toxic effects of the applied
MoAb on cell proliferation were observed (Fig 5B,
Control + aICAM-1 and Control + aCD44). The 30%±35%
increase of MM cell proliferation induced by HA (27,392 6 723
cpm on 0.1 mg per ml HA, 30,087 6 313 cpm on 1.0 mg per ml
HA, and 29,143 6 1471 cpm in the presence of 1 mg per ml sol
HA) was blocked completely through addition of anti-CD44
MoAb BU75 (Fig 5B, HA + aCD44), whereas a MoAb against
ICAM-1 had no effect (Fig 5B, HA + aICAM-1). Sera against
RHAMM/IHABP also had no in¯uence on the HA-induced
proliferation of melanoma cells (data not shown). The growth-
Figure 2. Upregulation of CD44, ICAM-1, and RHAMM/IHABP
mRNA transcription in human melanoma cell lines. Northern blot
analyses of nine human melanoma cell lines, four melanocyte preparations,
and one keratinocyte preparation are shown. Lanes 1±6, MM cell lines
MV3, HT144, 1F6, MM1, SB1, and SB3; lanes 7±10, melanocyte
preparations Mel1 P4, Mel2 P5, Mel3 P3, and Mel5 P5; lane 11,
keratinocytes P1. The blot was subsequently hybridized with [32P]-dCTP
labeled cDNA probes for panCD44, ICAM-1, and RHAMM/IHABP. As
control for equal loading, the ethidium bromide stain of the RNA gel is
shown.
Figure 3. Protein expression and cytoplasmic localization of
RHAMM/IHABP in MM cell lines. In (A) FACS stainings of the
surface expression of CD44 and ICAM-1 with MoAb against panCD44
(BU75), CD44v9 (FW11.24), and ICAM-1 (84H10) are shown for the
MM cell line 1F6. In (B) surface (M) and intracellular (C) stainings with
antihuman RHAMM/IHABP serum are shown for the MM cell line 1F6.
As negative controls, either a mouse IgG1a control MoAb or rabbit
preimmune serum (rab-Ctrl.) were used. In (C) Western blots of
subcellular protein fractions are depicted. Equal amounts of total cellular
protein lysate L, the membrane protein fraction M, and the cytoplasmic
protein fraction C of MV3 MM cells were separated by SDS-PAGE,
transferred to PVDF membranes, and incubated with MoAb against
panCD44 (Hermes3), IkB, and antihuman RHAMM/IHABP serum. In
(D) a Western blot of total protein lysates of six melanoma cell lines (MV3,
HT144, 1F6, MM1, SB1, and SB3), a primary melanocyte culture (Mel8
P4), the cervix carcinoma cell line HeLa, and the breast cancer cell lines
T47D and MCF7 was incubated with rabbit antihuman RHAMM/IHABP
serum. Incubating the blot with a serum against the intracellular ERK
protein was used as control for equal protein loading.
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promoting effect of high molecular weight HA was not observed
when small HA fragments (tetrasaccharide and hexasaccharide
units) generated by hyaluronidase digestion of high molecular
weight HA were added to MM cell cultures (data not shown).
Interactions of membrane-bound CD44 and high molecular weight
HA in summary clearly provide a growth stimulatory signal for
melanoma cells.
HA affects autocrine growth factor release by melanoma
cells HA stimulates the proliferation of different cell types, as
shown previously in other experimental systems (West and Kumar,
1989; Galandrini et al, 1994; Hamann et al, 1995; Kaya et al, 1997;
Ra® et al, 1997) and in this study for MM cells (Fig 5). Moreover,
the endogenous HA production of MM cells correlates with their
proliferative potential (Goebeler et al, 1996). All analyzed MM cell
lines used in this study but not primary melanocyte cultures have
been characterized by an enhanced HA release into the culture
supernatant (data not shown). These ®ndings suggest that the
expression of CD44 and the endogenous HA synthesis are related
to the proliferative capacity of MM cells. Several growth factors like
TGF-b1, IL-1a, IL-6, IL-8, PDGF-AB, Gro-a, and bFGF have
been described as autocrine growth factors for melanoma cells (Shih
and Herlyn, 1993). To analyze whether the interaction of CD44
with HA affects growth factor release by melanoma cells,
conditioned 48 h supernatants from the MM cell line MV3 were
tested for levels of bFGF, TGF-b1, Gro-a, IL-8, PDGF-AB, TNF-
a, and IL-6. The cultivation of cells on HA-precoated wells
resulted in a 300% increase of bFGF release (Fig 6A). In addition, a
70% induction of TGF-b1 secretion was observed (Fig 6B). The
secretion of other growth factors remained unaffected by HA (Gro-
a, PDGF-AB, IL-8) or was not detectable (IL-6, TNF-a, IL-1a,
and GM-CSF, data not shown). The HA-induced growth factor
release could not be blocked using anti-CD44 MoAb (data not
shown). Taking the partial inhibition of HA binding and adhesion
Figure 4. CD44 is the principal HA receptor on human melanoma
cells. Binding of soluble HA-FITC (HA-FITC) to the MM cell line MV3
is shown in (A). For blocking studies cells were preincubated with MoAb
anti-panCD44 (aCD44, BU75, or MEM85), anti-ICAM-1 (aICAM-1),
or irrelevant mouse IgG1a (mIgG1) at 20 mg per ml before adding HA-
FITC. As negative control, cells were incubated with unlabeled HA (HA).
Adhesion of HT144 cells to immobilized HA is shown in (B). 5 3 104
[3H]-thymidine labeled cells per well were allowed to adhere on HA-
coated wells for 30 min at 4°C. As controls for unspeci®c binding, cells
were also incubated on BSA-coated (1% BSA-Ctrl) or hyaluronidase
(HA + Hyaluronidase) treated wells. Blocking of HA binding was tested by
preincubation of MM cells with MoAb (10 mg per ml) against panCD44
and ICAM-1 or anti-RHAMM/IHABP sera. Cell adhesion was calculated
as percentage of adherent cells to total number of applied cells (= 100%).
Data are expressed as mean values of six wells 6 SD. One of three almost
identical experiments is shown. Similar results were obtained with the MM
cell lines MV3 and 1F6.
Figure 5. HA stimulates the proliferation of melanoma cells.
2500 MV3 (A) or HT144 (B) MM cells per well were cultured for 48 h
on HA-precoated wells (0.01, 0.1, or 1.0 mg per ml). Effects of soluble HA
were determined by addition of soluble HA to the culture medium at ®nal
concentrations of 0.1 or 1.0 mg per ml. Values represent (%) increase of
proliferation compared with the basal proliferation (= 100%) of cells
cultivated in the absence of HA. (B) shows one representative proliferation
blocking experiment with HT144 cells. HT144 were preincubated with
MoAb against pan-CD44 and ICAM-1 (10 mg per ml), plated on 96-well
plates, and labeled with 1 mCi [3H]-thymidine per well for a total of 48 h.
After 24 h, another 5 mg per ml of the indicated MoAb were added to the
culture medium. Cells were harvested after 48 h and [3H]-thymidine
uptake was determined. Data (mean value 6 SD of ®ve wells) are expressed
as (%) decrease/increase of proliferation compared with the basal
proliferation of cells cultivated in the absence of HA. Asterisks indicate a
statistically signi®cant induction of proliferation (Student's t test, p < 0.001)
compared to respective controls (without HA). One of three almost
identical experiments for each cell line is shown.
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by these antibodies (Fig 4) into account, it can be speculated that
alternative HA receptors substitute for CD44 in MM cells.
DISCUSSION
The expression of CD44s, CD44 variant isoforms, as well as
ICAM-1 have been discussed as prognostic markers in the course of
human MM (Johnson et al, 1989; Manten-Horst et al, 1995;
Dietrich et al, 1997). The expression of the alternative HA receptor
RHAMM/IHABP in MM has not been studied so far. In this study
we demonstrate the expression of CD44, ICAM-1, and RHAMM/
IHABP in tumor specimens of human melanoma in vivo and on
human melanoma cell lines in vitro. Elucidating a function of these
highly expressed proteins in MM, only CD44 was found to mediate
HA binding and HA-induced cell proliferation in melanoma cells.
Our comparative analysis of tumor sections from the precursor
lesions of MM, BMN, PMM, and MMM revealed an increased
expression of panCD44, ICAM-1, and RHAMM/IHABP during
melanoma progression. Northern blot analysis of a panel of MM
cell lines characterized by different growth potentials in nude mice
revealed high RHAMM/IHABP and ICAM-1 mRNA expression
in all MM cell lines but only low basal expression in non-
transformed cultured melanocytes. Increased levels of CD44
mRNA were detected in the cell lines MV3, HT144, and 1F6,
which are characterized by rapid local tumor formation in nu/nu
mice. The latter ®nding is consistent with previous reports
(Manten-Horst et al, 1995; Dietrich et al, 1997) where a correlation
of high CD44 expression in MM cells and tumor progression was
described. A basal expression of murine RHAMM/IHABP
mRNA has been observed previously in several tissues (Fieber
et al, 1999). We also detected basal expression levels of RHAMM/
IHABP in BMN and several preparations of nontransformed
melanocytes. The signi®cant upregulation of RHAMM/IHABP as
well as CD44 and ICAM-1 in different stages of MM tumorigen-
esis, however, prompted us to investigate possible functions of these
proteins in more detail.
The surface expression of CD44, ICAM-1, and RHAMM/
IHABP was analyzed in FACS and Western blot experiments. In
contrast to previous reports (Turley et al, 1991; Hardwick et al,
1992), which proposed that RHAMM/IHABP is a surface receptor
in association with a putative hyaluronan receptor complex called
HARC (Turley, 1992), we were unable to detect RHAMM/
IHABP on the surface of MM cells.
Instead, RHAMM/IHABP was expressed exclusively within the
cytoplasm of human melanoma cells, con®rming and extending
recent studies in human breast carcinoma cell lines (Assmann et al,
1998) and mouse ®brosarcoma cell lines (Hofmann et al, 1998a).
Consequently the protein was renamed IHABP (Hofmann et al,
1998a; and discussion in Hofmann et al, 1998b).
The contribution of CD44 on binding of melanoma cells to HA
was studied in adhesion assays using plastic-immobilized HA and
binding assays using soluble FITC-labeled HA. Preincubation of
MM cells with MoAb that interfere with the HA-binding function
of CD44 (Levesque and Haynes, 1996) reduced HA binding in
both assays by 60%. In contrast, MoAb against ICAM-1 or different
polyclonal rabbit sera against RHAMM/IHABP had no effect. We
conclude that CD44 is the principal surface receptor for exogenous
HA on human melanoma cells. Intracellular RHAMM/IHABP
does not contribute to surface binding of exogenous HA although
the capacity of the RHAMM/IHABP protein to bind HA has
clearly been shown (Assmann et al, 1998). The function of
cytoplasmic RHAMM/IHABP is currently under investigation
(Assmann et al, 1999).
The strong upregulation of CD44, ICAM-1, and RHAMM/
IHABP in vivo is closely related to growth potential and advanced
stages of human melanoma. Also, keeping the increased HA
synthesis of MM cells in mind (Goebeler et al, 1996; Ichikawa et al,
1999), one would expect physiologic consequences of HA±HAR
interactions in terms of proliferation or migration of MM cells.
Here we clearly demonstrate that HA promotes MM cell
proliferation, which, based on MoAb blocking studies, is critically
dependent upon interactions of HA with CD44. The induction of
MM cell proliferation mediated by HA was measured to be in the
range 30%±40%. We conclude that changes in CD44 surface
expression and HA levels in the ECM surrounding tumor cells
favor an increase of the proliferative potential of MM cells. These
results extend previous reports showing that proliferation of human
eosinophils or mouse spleen cells is dependent on CD44±HA
interactions (Hamann et al, 1995; Ra® et al, 1997). Furthermore,
loss of CD44 on the cell surface of mouse keratinocytes has been
shown to abolish HA binding, to reduce proliferation of
keratinocytes, but not to affect HA synthesis (Kaya et al, 1997).
The importance of HA±CD44 interactions for melanoma tumor
cell proliferation in vivo was demonstrated by rapid local tumor
growth of a wild-type CD44 expressing melanoma cell line after
injection into SCID nu/nu mice (Bartolazzi et al, 1994). Injection
of melanoma cells expressing CD44 defective in its HA-binding
function inhibited tumor cell proliferation (Bartolazzi et al, 1994).
MM cells express a variety of autocrine cytokines and growth
factors (Shih and Herlyn, 1993; Mattei et al, 1994). Cultivation of
MM cells on ®bronectin-coated surfaces upregulated the expression
of IL-1a, IL-6, IL-8, and TGF-b2 (Lupetti et al, 1996). For
coronary endothelial cells an increase of bFGF release into the
culture medium was observed upon cultivation of the cells on
collagen type IV, laminin, and ®bronectin (Albuquerque et al,
1998). A direct impact of HA on growth factor release of
melanoma cells has not been reported so far. Here we provide
evidence that culture of melanoma cells on HA-coated surfaces
leads to an increased release of bFGF and TGF-b1, whereas
secretion of Gro-a, PDGF-AB, IL-8, IL-6, TNF-a, IL-1a, and
GM-CSF remained unchanged.
The endogenous production of bFGF in MM is well known and
blocking of bFGF and bFGF-R in human melanomas reduces
tumor growth (Wang and Becker, 1997). How bFGF, which lacks
a signal peptide, is released from intracellular stores into the culture
medium still remains unclear. Exocytosis (Mignatti and Rifkin,
1991) or release through plasma membrane disruptions
(Muthukrishnan et al, 1991) are the pathways discussed for release
of bFGF into the culture supernatant. The function of TGF-b1 in
tumor progression is controversial. TGF-b1 is involved both as
suppressor of benign tumor outgrowth as well as enhancer of
malignant progression of murine invasive spindle carcinomas (Cui
et al, 1996). TGF-b was reported recently to trigger the
upregulation of HA synthase in mouse skin (Sugiyama et al,
1998). HA itself is the stimulus for enhanced TGF-b1 release in
melanoma cells, thus providing a feedback mechanism for its own
synthesis. In summary, TGF-b1 and bFGF most probably
contribute to the HA-induced increase of proliferation of MM
cells via an autocrine loop.
Figure 6. HA-induced secretion of growth factors in MM cell lines.
2500 MV3 MM cells per well were cultured on plastic dishes precoated
with HA (1 mg per ml). Cell culture supernatants of six wells were pooled.
After 48 h bFGF (A) and TGF-b1 (B) release was measured by ELISA
according to the manufacturer¢s instructions. Data are shown as mean
values of triplicate measurements 6 SD.
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We conclude that CD44 is the principal cell surface receptor for
HA on human melanoma cells. The binding of HA to CD44
markedly enhances the growth potential of melanoma cells in part
via the stimulation of an autocrine TGF-b1- and bFGF-dependent
loop. These ®ndings strongly support the notion that HA, which is
found at high concentrations in the stroma surrounding melano-
mas, can enhance tumor growth through interaction with its
principal surface receptor CD44.
We thank Brigitte Mai and Anke Stingl for expert technical assistance. In addition,
we thank C. V. Hamby for kindly providing us with the SB1 and SB3 melanoma
cell lines and G. N. van Muijen for sending us the MV3 and 1F6 melanoma cell
lines. The ICAM-1 cDNA was kindly provided by J. P. Johnson. This work was
supported by grant He 551/8/1±2 from the Deutsche Forschungsgemeinschaft.
REFERENCES
Albuquerque ML, Akiyama SK, Schnaper HW: Basic ®broblast growth factor release
by human coronary artery endothelial cells is enhanced by matrix proteins,
17beta-estradiol, and a PKC signaling pathway. Exp Cell Res 245:163±169,
1998
Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B: CD44 is the principal
cell surface receptor for hyaluronate. Cell 61:1303±1313, 1990
Assmann V, Kern HF, Elsaesser HP: Differential expression of the hyaluronan
receptors CD44 and RHAMM in human pancreatic cancer cells. Clin Cancer
Res 2:1607±1618, 1996
Assmann V, Marshall JF, Fieber C, Hofmann M, Hart IR: The human hyaluronan
receptor RHAMM is expressed as an intracellular protein in breast cancer cells.
J Cell Sci 111:1685±1694, 1998
Assmann V, Jenkinson D, Marshall JF, Hart IR: The intracellular hyaluronan receptor
RHAMM/IHABP interacts with microtubules and actin ®laments. J Cell Sci
112:3943±3954, 1999
Bajorath J, Green®eld B, Munro SB, Day AJ, Aruffo A: Identi®cation of CD44
residues important for hyaluronan binding and delineation of the binding site. J
Biol Chem 273:338±343, 1998
Banerji S, Ni J, Wang SX, et al: LYVE-1, a new homologue of the CD44
glycoprotein, is a lymph-speci®c receptor for hyaluronan. J Cell Biol 144:789±
801, 1999
Bartolazzi A, Peach R, Aruffo A, Stamenkovic I: Interaction between CD44 and
hyaluronate is directly implicated in the regulation of tumor development. J
Exp Med 180:53±66, 1994
de Belder AN, Wik KO: Preparation and properties of ¯uorescein-labelled
hyaluronate. Carbohydr Res 44:251±257, 1975
Boulton TG, Nye SH, Robbins DJ, et al: ERKs: a family of protein-serine/threonine
kinases that are activated and tyrosine phosphorylated in response to insulin and
NGF. Cell 65:663±675, 1991
Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem
162:156±159, 1987
Cui W, Fowlis DJ, Bryson S, Duf®e E, Ireland H, Balmain A, Akhurst RJ: TGFbeta1
inhibits the formation of benign skin tumors, but enhances progression to
invasive spindle carcinomas in transgenic mice. Cell 86:531±542, 1996
Dall P, Heider KH, Hekele A, von Minckwitz G, Kaufmann M, Ponta H, Herrlich
P: Surface protein expression and messenger RNA-splicing analysis of CD44 in
uterine cervical cancer and normal cervical epithelium. Cancer Res 54:3337±
3341, 1994
Delpech B, Girard N, Bertrand P, Courel MN, Chauzy C, Delpech A: Hyaluronan:
fundamental principles and applications in cancer. J Intern Med 242:41±48, 1997
Dietrich A, Tanczos E, Vanscheidt W, Schopf E, Simon JC: High CD44 surface
expression on primary tumours of malignant melanoma correlates with
increased metastatic risk and reduced survival. Eur J Cancer 33:926±930, 1997
Fidler IJ: Critical determinants of melanoma metastasis. J Invest Dermatol Symp Proc
The 1:203±208, 1996
Fieber C, Plug R, Sleeman J, Dall P, Ponta H, Hofmann M: Characterisation of the
murine gene encoding the intracellular hyaluronan receptor IHABP
(RHAMM). Gene 226:41±50, 1999
Galandrini R, Galluzzo E, Albi N, Grossi CE, Velardi A: Hyaluronate is
costimulatory for human T cell effector functions and binds to CD44 on
activated T cells. J Immunol 153:21±31, 1994
Goebeler M, Kaufmann D, Brocker EB, Klein CE: Migration of highly aggressive
melanoma cells on hyaluronic acid is associated with functional changes,
increased turnover and shedding of CD44 receptors. J Cell Sci 109:1957±1964,
1996
Gustafson S, Bjorkman T, Forsberg N, Lind T, Wikstrom T, Lidholt K: Accessible
hyaluronan receptors identical to ICAM-1 in mouse mast-cell tumours.
Glycoconj J 12:350±355, 1995
Hall CL, Yang B, Yang X, et al: Overexpression of the hyaluronan receptor
RHAMM is transforming and is also required for H-ras transformation. Cell
82:19±26, 1995
Hamann KJ, Dowling TL, Neeley SP, Grant JA, Leff AR: Hyaluronic acid enhances
cell proliferation during eosinopoiesis through the CD44 surface antigen. J
Immunol 154:4073±4080, 1995
Hardwick C, Hoare K, Owens R, et al: Molecular cloning of a novel hyaluronan
receptor that mediates tumor cell motility. J Cell Biol 117:1343±1350, 1992
Heider KH, Hofmann M, Hors E, van den Berg F, Ponta H, Herrlich P, Pals ST: A
human homologue of the rat metastasis-associated variant of CD44 is expressed
in colorectal carcinomas and adenomatous polyps. J Cell Biol 120:227±233,
1993
Herlyn M: Human melanoma: development and progression. Cancer Metastasis Rev
9:101±112, 1990
Hofmann M, Fieber C, Assmann V, et al: Identi®cation of IHABP, a 95 kDa
intracellular hyaluronate binding protein. J Cell Sci 111:1673±1684, 1998a
Hofmann M, Assmann V, Fieber C, et al: Problems with RHAMM. A new link
between surface adhesion and oncogenesis? Cell 95:591±592, 1998b
Horst E, Meijer CJ, Radaszkiewicz T, Ossekoppele GJ, Van Krieken JH, Pals ST:
Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression
of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1
(CD54). Leukemia 4:595±599, 1990
Ichikawa T, Itano N, Sawai T, Kimata K, Koganehira Y, Saida T, Taniguchi S:
Increased synthesis of hyaluronate enhances motility of human melanoma cells.
J Invest Dermatol 113:935±939, 1999
Iozzo RV, Murdoch AD: Proteoglycans of the extracellular environment: clues from
the gene and protein side offer novel perspectives in molecular diversity and
function. Faseb J 10:598±614, 1996
Joensuu H, Klemi PJ, Toikkanen S, Jalkanen S: Glycoprotein CD44 expression and
its association with survival in breast cancer. Am J Pathol 143:867±874, 1993
Johnson JP, Stade BG, Holzmann B, Schwable W, Riethmuller G: De novo
expression of intercellular-adhesion molecule 1 in melanoma correlates with
increased risk of metastasis. Proc Natl Acad Sci USA 86:641±644, 1989
Kaya G, Rodriguez I, Jorcano JL, Vassalli P, Stamenkovic I: Selective suppression of
CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by
a tissue-speci®c promoter disrupts hyaluronate metabolism in the skin and
impairs keratinocyte proliferation. Genes Dev 11:996±1007, 1997
Knudson W, Biswas C, Li XQ, Nemec RE, Toole BP: The role and regulation of
tumour-associated hyaluronan. Ciba Found Symp 143:150±159, 1989
Laurent TC, Fraser JR: Hyaluronan. Faseb J 6:2397±2404, 1992
Lesley J, Hyman R, Kincade PW: CD44 and its interaction with extracellular matrix.
Adv Immunol 54:271±335, 1993
Levesque MC, Haynes BF: In vitro culture of human peripheral blood monocytes
induces hyaluronan binding and up-regulates monocyte variant CD44 isoform
expression. J Immunol 156:1557±1565, 1996
Lupetti R, Mortarini R, Panceri P, Sensi M, Anichini A: Interaction with ®bronectin
regulates cytokine gene expression in human melanoma cells. Int J Cancer
66:110±116, 1996
Manten-Horst E, Danen EH, Smit L, et al: Expression of CD44 splice variants in
human cutaneous melanoma and melanoma cell lines is related to tumor
progression and metastatic potential. Int J Cancer 64:182±188, 1995
Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M: Expression of
cytokine/growth factors and their receptors in human melanoma and
melanocytes. Int J Cancer 56:853±857, 1994
Mayer B, Jauch KW, Gunthert U, Figdor CG, Schildberg FW, Funke I, Johnson JP:
De-novo expression of CD44 and survival in gastric cancer. Lancet 342:1019±
1022, 1993
McCourt PA, Gustafson S: On the adsorption of hyaluronan and ICAM-1 to
modi®ed hydrophobic resins. Int J Biochem Cell Biol 29:1179±1189, 1997
McCourt PA, Ek B, Forsberg N, Gustafson S: Intercellular adhesion molecule-1 is a
cell surface receptor for hyaluronan. J Biol Chem 269:30081±30084, 1994
Mignatti P, Rifkin DB: Release of basic ®broblast growth factor, an angiogenic factor
devoid of secretory signal sequence: a trivial phenomenon or a novel secretion
mechanism? J Cell Biochem 47:201±207, 1991
van Muijen GN, Danen EH, Veerkamp JH, Ruiter DJ, Lesley J, van den Heuvel LP:
Glycoconjugate pro®le and CD44 expression in human melanoma cell lines
with different metastatic capacity. Int J Cancer 61:241±248, 1995
Muthukrishnan L, Warder E, McNeil PL: Basic ®broblast growth factor is ef®ciently
released from a cytolsolic storage site through plasma membrane disruptions of
endothelial cells. J Cell Physiol 148:1±16, 1991
Naor D, Sionov RV, Ish-Shalom D: CD44: structure, function, and association with
the malignant process. Adv Cancer Res 71:241±319, 1997
Penno MB, August JT, Baylin SB, et al: Expression of CD44 in human lung tumors.
Cancer Res 54:1381±1387, 1994
Ra® A, Nagarkatti M, Nagarkatti PS: Hyaluronate±CD44 interactions can induce
murine B-cell activation. Blood 89:2901±2908, 1997
Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI: Genomic
structure of DNA encoding the lymphocyte homing receptor CD44 reveals at
least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89:12160±12164,
1992
Shih IM, Herlyn M: Role of growth factors and their receptors in the development
and progression of melanoma. J Invest Dermatol 100:196S±203S, 1993
Simon JC, Heider KH, Dietrich A, et al: Expression of CD44 isoforms in human skin
cancer. Eur J Cancer 32A:1394±1400, 1996
Sleeman JP, Kondo K, Moll J, Ponta H, Herrlich P: Variant exons v6 and v7 together
expand the repertoire of glycosaminoglycans bound by CD44. J Biol Chem
272:31837±31844, 1997
Sugiyama Y, Shimada A, Sayo T, Sakai S, Inoue S: Putative hyaluronan synthase
mRNA are expressed in mouse skin and TGF-beta upregulates their expression
in cultured human skin cells. J Invest Dermatol 110:116±121, 1998
Teder P, Bergh J, Heldin P: Functional hyaluronan receptors are expressed on a
100 AHRENS ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
squamous cell lung carcinoma cell line but not on other lung carcinoma cell
lines. Cancer Res 55:3908±3914, 1995
Thomas L, Byers HR, Vink J, Stamenkovic I: CD44H regulates tumor cell migration
on hyaluronate-coated substrate. J Cell Biol 118:971±977, 1992
Turley EA: Hyaluronan and cell locomotion. Cancer Metastasis Rev 11:21±30, 1992
Turley EA, Austen L, Vandeligt K, Clary C: Hyaluronan and a cell-associated
hyaluronan binding protein regulate the locomotion of ras-transformed cells. J
Cell Biol 112:1041±1047, 1991
Wang Y, Becker D: Antisense targeting of basic ®broblast growth factor and
®broblast growth factor receptor-1 in human melanomas blocks intratumoral
angiogenesis and tumor growth. Nat Med 3:887±893, 1997
Wang C, Entwistle J, Hou G, Li Q, Turley EA: The characterization of a human
RHAMM cDNA. Conservation of the hyaluronan-binding domains. Gene
174:299±306, 1996
West DC, Kumar S: The effect of hyaluronate and its oligosaccharides on endothelial
cell proliferation and monolayer integrity. Exp Cell Res 183:179±196, 1989
Wielenga VJ, Heider KH, Offerhaus GJ, et al: Expression of CD44 variant proteins in
human colorectal cancer is related to tumor progression. Cancer Res 53:4754±
4756, 1993
Yang B, Yang BL, Savani RC, Turley EA: Identi®cation of a common hyaluronan
binding motif in the hyaluronan binding proteins RHAMM, CD44 and link
protein. Embo J 13:286±296, 1994
Zhang L, Underhill CB, Chen L: Hyaluronan on the surface of tumor cells is
correlated with metastatic behavior. Cancer Res 55:428±433, 1995
VOL. 116, NO. 1 JANUARY 2001 CD44±HA INTERACTIONS AND MELANOMA 101
